Avigen About
Avigen: Avigen is a leader in the development of gene
therapy products to treat serious, chronic diseases. Their gene therapy products
are designed for in vivo administration to achieve the production of therapeutic
proteins within the body. Avigen believes AAV vectors can be used to deliver genes
for Parkinson's disease, Chronic Neuropathic Pain, Hemophilia (A and B), and many
other diseases. Clinical Developments --The Food and Drug Administration
(FDA) has authorized Avigen to initiate a Phase I-II clinical trial of AV201,
its treatment for severe Parkinson's disease. In December, 2004, the company began
the Phase I/II clinical trial for AV201 at the University of California San Francisco
(UCSF). Avigen’s AV201 is designed to restore the therapeutic effectiveness of
levodopa by putting the gene for AADC into the striatum of the brain of patients
with advanced Parkinson’s disease so that they will respond to a lower dose of
levodopa and not experience debilitating side effects. Avigen's AAV
Vector Technology Avigen's gene therapy products are based on gene delivery
systems called vectors. AAV vectors are derived from AAV, a common non-pathogenic
human virus, and take advantage of the natural efficiency with which viruses deliver
genes to cells. Pipeline:
AV201
for the Treatment of Severe Parkinson’s Disease
More on Avigen:
Key
Statistics fo
Avigin
Basic Chart
for Avigin